Refractory myasthenia gravis. Objective: To demonstrate a case of Myasthenia Grav...

Muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG

Oct 11, 2021 · Myasthenia gravis (MG) is a rare classic autoimmune disease where immunosuppressant therapies have been successful to reduce MG attributable mortality fairly well. However, patients with refractory MG (rMG) among the actively treated MG (aMG) are nonresponsive ... Abstract: Introduction: Myasthenia gravis, an autoimmune disorder of neuromuscular transmission, is treated by an array of immunomodulating therapies.Introduction Myasthenia gravis (MG) is a rare, debilitating, chronic disorder caused by the production of pathogenic immunoglobulin G autoantibodies against the neuromuscular junction. A lack of real-world studies in rare diseases reflects a relatively limited understanding of the significant unmet needs and burden of disease for patients. We aimed to provide comprehensive real-world insights ...Introduction. Myasthenia gravis (MG) is an autoimmune condition of the neuromuscular junction, characterized by weak and fatigable skeletal muscles.1 Approximately 80–85% of MG patients respond favorably to available immunosuppressive therapies, which include steroids, azathioprine (Az), mycophenolate mofetil (MM), cyclosporine (Cy), intravenous immunoglobulin (IVIG), plasma exchange (PLEX ...The findings suggest that, although most patients with refractory gMG will achieve clinical response by Week 12 of eculizumab treatment, first responses can be observed with longer-term treatment. ... Generalized myasthenia gravis (gMG) is an autoimmune disease that causes disabling weakness via damage to the neuromuscular junction. In most ...Feb 12, 2018 · Abstract. The humanized monoclonal antibody eculizumab (Soliris ®) is a complement inhibitor indicated for use in anti-acetylcholine receptor (AChR) antibody-positive adults with generalized myasthenia gravis (gMG) in the USA, refractory gMG in the EU, or gMG with symptoms that are difficult to control with high-dose IVIg therapy or PLEX in Japan. Myasthenia gravis (MG) treatments include acetylcholinesterase inhibitors, such as pyridostigmine and corticosteroids, at different doses. ... thymectomy is another option. 3 Between 10% and 30% of patients with MG have treatment-refractory disease and remain symptomatic despite use of at least 2 immunosuppressants, have frequent relapses ...Oct 11, 2021 · Myasthenia gravis (MG) is a rare classic autoimmune disease where immunosuppressant therapies have been successful to reduce MG attributable mortality fairly well. However, patients with refractory MG (rMG) among the actively treated MG (aMG) are nonresponsive ... In 2020, the American Academy of Neurology published an updated version of the International Consensus Guidance on Management of Myasthenia Gravis, which formally recommends the use of eculizumab for patients with severe, treatment-refractory, AChR+ gMG.46 While the approval of eculizumab undoubtedly represents a huge step forward in the ...An early onset of myasthenia gravis was associated with a higher risk for a refractory course. Conclusion A small subgroup of patients with generalized myasthenia gravis do not respond sufficiently to standard therapies.SYSTEMATIC REVIEW article Front. Neurol., 13 October 2021 Sec. Neuromuscular Disorders and Peripheral Neuropathies Volume 12 - 2021 | https://doi.org/10.3389/fneur.2021.736190 Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-AnalysisHarris L, Aban IB, Xin H, Cutter G. Employment in refractory myasthenia gravis: A Myasthenia Gravis Foundation of America Registry analysis. Muscle Nerve. 2019;60(6):700-706. Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134. Gilhus NE. Objectives: Myasthenia gravis (MG) is an immune-mediated neuromuscular disorder responsive to immunomodulatory treatments. 10–20% of MGs are not responsive to conventional first-line therapies. Here, we sought to investigate the efficacy and safety of rituximab therapy in the treatment of patients with refractory MG. Methods: In a 48 …All the above-mentioned favorable outcomes of rituximab in refractory myasthenia gravis patients have widened the options for treatment of refractory myasthenia gravis; they have also demonstrated that RTX could improve patients' quality of life by decreasing dose-related adverse effects and sustaining remission [10,12-17]. Even though RMG ...We describe a case of refractory myasthenia gravis with bulbar involvement and the nutritional treatment solutions proposed to treat the associated dysphagia and malnutrition. Methods. A 39-y-old woman with refractory myasthenia gravis was referred to our clinical nutrition unit for deteriorating dysphagia and progressive malnutrition.Jan 1, 2021 · Patients Who Achieved Myasthenia Gravis Foundation of America Post-intervention Status of Improved or Minimal Manifestations at REGAIN (Safety and Efficacy of Eculizumab in Anti-acetylcholine Receptor-Positive Refractory Generalized Myasthenia Gravis) Weeks 4, 12, and 26, and Open-Label Study Weeks 26, 52, 78, 104, and 130 Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome - PMC. Journal List. Ann Clin Transl Neurol. v.9 (2); 2022 Feb. PMC8862423. As a …Autologous Hematopoietic Stem Cell Transplant for the Treatment of Refractory Myasthenia Gravis with Anti-Muscle Specific Kinase Antibodies Muscle Nerve. 2022 Dec 17. doi: 10.1002/mus.27772. ... The average worst Myasthenia Gravis Activities of Daily Living (MG-ADL) scores improved from 14.7 before to 0.3 after HSCT. ...Vissing J, O’Brien F, Wang JJ, et al. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 REGAIN study.A series of patients with refractory myasthenia gravis. 2020 Nov 7;S0213-4853 (20)30293-0. doi: 10.1016/j.nrl.2020.08.016. Online ahead of print. Advances in the treatment of myasthenia gravis (MG) have improved quality of life and prognosis for the majority of patients. However, 10%-20% of patients present refractory MG, with frequent relapses ...The term myasthenia gravis (MG) is derived from the Greek terms my, asthenia, and gravis, which mean muscle, weakness, and severe, respectively. ... Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: A retrospective study. Therapeutic Advances in Neurological Disorders. 2011; …Patients with myasthenia gravis (MG) who do not respond to conventional immunotherapeutic agents, or cannot tolerate their side effects, are considered "refractory." Ablation of the immune system followed by bone marrow transplant has been shown to cure experimental MG in rats. It is now known that …When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord . 2018;11:1756285617749134. Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients.Myasthenia gravis is an autoimmune disease affecting the neuromuscular junction, often associated with other autoimmune diseases, including rheumatoid arthritis. ... Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscul Disord NMD. 2017; 27:565–568. doi: …Myasthenia gravis (MG) is a chronic autoimmune disease mediated by antibodies against post-synaptic proteins of the neuromuscular junction. Up to 10%–30% of patients are refractory to …Introduction: This study assessed the clinical burden of refractory myasthenia gravis (MG), relative to nonrefractory MG. Methods: Rates of myasthenic crises, exacerbations, inpatient hospitalizations, and emergency room (ER) visits over a 1-year period were measured for 403 refractory, 3,811 nonrefractory, and 403 non-MG control patients from two administrative health plan databases.Grayson Beecher. 29742795. 10.1002/mus.26156. Rituximab appears to be beneficial in treatment-refractory myasthenia gravis (MG); however, prospective, long-term durability data are lacking. In this prospective, open-label study of rituximab in refractory MG, 22 patients (10 nicotinic acetylcholine receptor, 9 muscle-specific tyrosine kinase, 3 ...19 сент. 2014 г. ... Conclusion: Our results indicate that blepharoptosis surgery is effective for patients with myasthenia gravis, especially those with residual ...To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment. Methods. This observational retrospective cross-sectional multicenter study was based on data from the Spanish MG Registry (NMD-ES). Patients were ...Myasthenia gravis and Lambert-Eaton myasthenic syndrome are antibody-mediated autoimmune diseases of the neuromuscular junction that usually present with weakness in ocular muscles and in proximal muscles of the limb and trunk. Prognosis regarding muscle strength, functional abilities, quality of life, and survival is generally good. However, some patients do …Introduction. Generalized myasthenia gravis (gMG) is an autoimmune disorder characterized by muscle weakness that worsens with muscle use [1, 2].Symptoms associated with gMG include muscle weakness resulting in dysarthria, dysphagia, dyspnoea and fatigue in the muscles of the face, neck, arms, hands and legs [].Although there is no generally recognized …In these cases, individualized treatment strategies involving other immunomodulatory therapies, such as eculizumab or rituximab, may be considered., In October 2020, the CADTH Canadian Drug Expert Committee assessed the use of eculizumab for the treatment of adult patients with refractory generalized myasthenia gravis and gave a conditional ...Background and purpose: Defining refractory myasthenia gravis is important, as this can drive clinical decision making, for example, by escalating treatments in refractory individuals. There are several definitions of refractory myasthenia, and their performances have not been compared. Having valid and reliable criteria can help select patients in …Overview. Myasthenia gravis (MG) is an autoimmune disorder caused by antibodies that act against the myoneural junction. Conventional immunosuppressants such as corticosteroids, azathioprine and mycophenolate are associated with long-term side effects and many patients do not achieve remission and may become refractory.Jul 20, 2022 · Introduction Myasthenia gravis (MG) is a rare, debilitating, chronic disorder caused by the production of pathogenic immunoglobulin G autoantibodies against the neuromuscular junction. A lack of real-world studies in rare diseases reflects a relatively limited understanding of the significant unmet needs and burden of disease for patients. We aimed to provide comprehensive real-world insights ... Myasthenia gravis (MG) is a rare classic autoimmune disease where immunosuppressant therapies have been successful to reduce MG attributable mortality fairly well. However, patients with refractory MG (rMG) among the actively treated MG (aMG) are nonresponsive to conventional therapy and display high disease severity, which calls for further ...Introduction. Acquired myasthenia gravis (MG) is caused by an autoreactive humoral response against the postsynaptic end plate of the neuromuscular junction, with a prevalence of 24.8 to 27.8 per 100 000 in a Swedish nationwide study. 1,2 Myasthenia gravis can be stratified based on age, autoantibodies, presence of thymoma, and clinical …Jan 1, 2021 · This updated formal consensus guidance of international MG experts, based on new evidence, provides recommendations to clinicians caring for patients with MG worldwide. Evidence-based recommendations for the treatment of myasthenia gravis (MG) have historically been difficult to develop because of limited evidence from studies with a low risk ... SYSTEMATIC REVIEW article. Front. Neurol., 13 October 2021. Sec. Neuromuscular Disorders and Peripheral Neuropathies. Volume 12 - 2021 | …The primary efficacy endpoint was the change of the MG-ADL score from baseline to week 26. Ravulizumab was more effective than placebo in improving MG-ADL (−3.1 vs 1.4) …13 июн. 2023 г. ... Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are ...Myasthenia gravis (MG) is the most common disorder of neuromuscular transmission and is a prototypical autoimmune disorder. Most patients with MG are successfully treated with acetylcholinesterase ...Myasthenia gravis (MG) is an autoimmune neuromuscular disease that causes weakness of skeletal muscles, usually first manifesting as droopy eyelids and double vision [1,2]. In most cases, it ...In 2020, the American Academy of Neurology published an updated version of the International Consensus Guidance on Management of Myasthenia Gravis, which formally recommends the use of eculizumab for patients with severe, treatment-refractory, AChR+ gMG.46 While the approval of eculizumab undoubtedly represents a huge step …Oct 13, 2021 · Keywords: myasthenia gravis, refractory, rituximab, effectiveness, meta-analysis Introduction Myasthenia gravis (MG) is an acquired autoimmune disease of the neuromuscular junction (NMJ) characterized by partial or systemic skeletal muscle weakness and fatigability typically worsening after activity ( 1 ). Turkey gravy is not hard to make, but that does not stop some people from feeling very anxious about it. This actually makes sense to me: If you’ve never taken a thin liquid and made it thick, the process is quite mystifying. In reality tho...Myasthenia gravis (MG) is an autoantibody-mediated disease that compromises the acetylcholine receptors or associated structures of the postsynaptic membrane of the neuromuscular junction. This leads to impaired neuromuscular transmission and subsequent fluctuating fatigability and weakness of ocular, bulbar, and limb skeletal muscles.Vissing J, O’Brien F, Wang JJ, et al. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of …Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by fatigable muscle weakness. MG is specifically thought to be an antibody-mediated disease. MG can be treated, but a subset of patients remains refractory to conventional therapies, leading to refractory generalized myasthenia gravis (gMG).Myasthenia gravis (MG) is the most common disorder of neuromuscular transmission and is a prototypical autoimmune disorder. Most patients with MG are successfully treated with acetylcholinesterase inhibitors, corticosteroids, and/or steroid sparing agents such as azathioprine and mycophenolate mofetil.Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone J Clin Neurosci , 13 ( 1 ) ( 2006 ) , pp. 39 - 44 View PDF View article View in Scopus Google ScholarObjective Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction. However, evidence shaping treatment decisions, particularly for treatment-refractory cases, is sparse. Both rituximab and eculizumab may be considered as therapeutic options for refractory MG after insufficient symptom control by standard …A retrospective, longitudinal, cohort study was conducted of patients in England aged ≥ 18 years with treatment-refractory or non-refractory MG, using data recorded during 1997–2016 in the Clinical Practice Research Datalink and the Hospital Episode Statistics databases. A control cohort of patients without MG, matched to the patients in ...Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 2017; 16:976–986. [Google Scholar]Burden of refractory myasthenia gravis. To understand the burden that refractory MG places on patients, it is necessary to consider the clinical symptoms of the disease, the side effects of medications and surgery, the psychiatric burden, and the impact on quality of life (QoL). However, published information is limited, possibly owing to the ...Myasthenia gravis (MG) is a rare classic autoimmune disease where immunosuppressant therapies have been successful to reduce MG attributable mortality fairly well. However, patients with refractory MG (rMG) among the actively treated MG (aMG) are nonresponsive ...Clinical status and severity were determined by the recommendations of the Myasthenia Gravis Foundation of America. Results: Of 1388 patients with MG, 12 (0.9%) patients received eculizumab. A total of 11 patients who were anti-acetylcholine receptor antibody-positive with refractory gMG (M:F = 3:8) completed the 26-week treatment with eculizumab.5 янв. 2015 г. ... ABSTRACT… Myasthenia gravis (MG) is prototypical neurological autoimmune disorder, characterized by limb and occulo-bulbular fragility.A proportion of myasthenia gravis patients are classified as refractory due to non responsiveness to conventional treatment. This retrospective study was done to evaluate clinical profile, epidemiological, laboratory, and features of patients with MG and mode of management using rituximab and complications.Nov 9, 2021 · All the above-mentioned favorable outcomes of rituximab in refractory myasthenia gravis patients have widened the options for treatment of refractory myasthenia gravis; they have also demonstrated that RTX could improve patients' quality of life by decreasing dose-related adverse effects and sustaining remission [10,12-17]. Even though RMG ... Introduction: Myasthenia gravis (MG) is an autoimmune disease mediated by circulating autoantibodies (anti-AchR, anti-MuSK, etc.). More than 20% of myasthenic patients are refractory to conventional treatments (plasma exchange, IVIg, steroids, azathioprine, mycophenolate mofetil).Side effects, which usually are mild, can include chills, dizziness, headaches and fluid retention. Monoclonal antibody. Rituximab (Rituxan) and eculizumab (Soliris) are medicines given by vein for myasthenia gravis. These medicines are usually used when other treatments don't work. They can have serious side effects.Myasthenia gravis (MG) is a rare autoimmune disease characterised by antibody-mediated interference with neuromuscular transmission at the neuromuscular junction [].MG is classed as a rare disease, and its prevalence is estimated to be about 1–2 per 10,000 people [].However, reported incidence rates are increasing, partly due to …Abstract. Objective: To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment. Methods: This observational retrospective cross-sectional multicenter study was based on data from the Spanish MG Registry (NMD-ES).Abstract. Objective: To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment. Methods: This observational retrospective cross-sectional multicenter study was based on data from the Spanish MG Registry (NMD-ES). Myasthenia gravis (MG) is the most common disorder of neuromuscular transmission and is a prototypical autoimmune disorder. Most patients with MG are successfully treated with acetylcholinesterase inhibitors, corticosteroids, and/or steroid sparing agents such as azathioprine and mycophenolate mofetil.The humanized monoclonal antibody eculizumab (Soliris ®) is a complement inhibitor indicated for use in anti-acetylcholine receptor (AChR) antibody-positive adults with generalized myasthenia gravis (gMG) in the USA, refractory gMG in the EU, or gMG with symptoms that are difficult to control with high-dose IVIg therapy or PLEX in Japan. Abstract. The humanized monoclonal antibody eculizumab (Soliris ®) is a complement inhibitor indicated for use in anti-acetylcholine receptor (AChR) antibody-positive adults with generalized myasthenia gravis (gMG) in the USA, refractory gMG in the EU, or gMG with symptoms that are difficult to control with high-dose IVIg therapy or PLEX in Japan.Myasthenia gravis (MG) is the most common disorder of neuromuscular transmission and is a prototypical autoimmune disorder. Most patients with MG are successfully treated with acetylcholinesterase inhibitors, corticosteroids, and/or steroid sparing agents such as azathioprine and mycophenolate mofetil.Introduction: This study assessed the clinical burden of refractory myasthenia gravis (MG), relative to nonrefractory MG. Methods: Rates of myasthenic crises, exacerbations, inpatient hospitalizations, and emergency room (ER) visits over a 1-year period were measured for 403 refractory, 3,811 nonrefractory, and 403 non-MG control patients from two administrative health plan databases. Introduction. The main reason for the development of new therapeutic strategies in MG is the need for more specific and more effective drugs in particular in so-called refractory or difficult-to-treat/treatment resistant autoimmune myasthenia gravis. 1,2 The inability to achieve sufficient clinical improvement with minimal symptom expression …Vissing J, O’Brien F, Wang JJ, et al. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 REGAIN study.May 9, 2022 · Background Patients with generalized myasthenia gravis (MG) often experience debilitating exacerbations, with the possibility of life-threatening respiratory crises requiring hospitalization. Long-term longitudinal studies are needed to understand the burden of MG, including in patients whose disease is refractory to conventional treatment. Methods A retrospective, longitudinal, cohort study ... Clinical characteristics of refractory myasthenia gravis patients. 2013 Jun 13;86 (2):255-60. Jonathan M Goldstein. PMC3670444. A subset of myasthenia gravis (MG) patients is refractory to standard therapies. Identifying the characteristics of this population is essential as newer treatment strategies emerge that may be more effective …Clinical status and severity were determined by the recommendations of the Myasthenia Gravis Foundation of America. Results: Of 1388 patients with MG, 12 (0.9%) patients received eculizumab. A total of 11 patients who were anti-acetylcholine receptor antibody-positive with refractory gMG (M:F = 3:8) completed the 26-week treatment with eculizumab.Introduction. Myasthenia gravis (MG) is an antibody-mediated autoimmune disease characterized by fatigable muscle weakness. It is the most frequent neuromuscular junction disorder, with an overall prevalence rate of 15-179 per million individuals [].Eighty percent of MG patients have antibody production against the nicotinic acetylcholine receptor (AchR) in the …The following keywords were used: "myasthenia gravis," "rituximab," "monoclonal antibody," "anti-AChR antibody," and "refractory myasthenia." The review focused on case reports, human studies, or research surveys based on the inclusion criteria of human studies involving participants more than 18 years of age and published in …Myasthenia gravis is a neuromuscular autoimmune disease characterized by fatigable weakness of skeletal muscles that results from an antibody-mediated immunological attack directed at acetylcholine postsynaptic receptors. Autologous hematopoietic stem cell transplantation is considered as a treatment option in refractory cases of myasthenia gravis.Myasthenia gravis (MG) is an autoimmune neuromuscular disease that causes weakness of skeletal muscles, usually first manifesting as droopy eyelids and double vision [1,2]. In most cases, it ...Gotterer L, Li Y. Maintenance immunosuppression in myasthenia gravis. J Neurol Sci. 2016 Oct 15;369:294–302 [Web of Science ®], [Google Scholar] Schneider-Gold C, Hagenacker T, Melzer N, et al. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019 Feb;12:1756286419832242.Objective To assess rituximab in refractory and new-onset generalized myasthenia gravis and rituximab vs conventional immunotherapy in new-onset disease. Design, Setting, and Participants A retrospective cohort study with prospectively collected data was conducted on a county-based community sample at Karolinska University Hospital, Stockholm ... Furthermore, refractory patients may be at greater risk of crises throughout the disease course than previous studies have suggested. Muscle Nerve, 2018. Keywords: burden; myasthenia gravis; myasthenic crises; myasthenic exacerbations; refractory; utilization.To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment. Methods. This observational retrospective cross-sectional multicenter study was based on data from the Spanish MG Registry (NMD-ES). Patients were ...Our patient has had a refractory course with respect to myasthenia gravis. Other options for treatment of refractory myasthenia gravis include rituximab, high-dose cyclophosphamide and eculizumab . Given our patient’s progression of both autoimmune diseases, we explored the possibility of hematopoietic stem cell transplant (HSCT).Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar Farzad Fatehi , 1 Kamyar Moradi , 1 Ali Asghar Okhovat , 1 , 2 Ghazaleh Shojatalab , 1 Behnaz Sedighi , 3 Reza Boostani , 4 Payam Sarraf , 5 , 6 Bahram Haghi Ashtiani , 7 Majid Ghasemi , 8 Soussan ...Mar 1, 2019 · Understanding the burden of refractory myasthenia gravis Abstract. Myasthenia gravis (MG) is an autoantibody-mediated disease that compromises the acetylcholine receptors or... Introduction. Myasthenia gravis (MG) is a rare, antibody-mediated autoimmune disease of the neuromuscular junction,... ... All the above-mentioned favorable outcomes of rituximab in refractory myasthenia gravis patients have widened the options for treatment of refractory myasthenia gravis; they have also demonstrated that RTX could improve patients' quality of life by decreasing dose-related adverse effects and sustaining remission [10,12-17]. …. Vissing J, O’Brien F, Wang JJ, et al. Correlation betweenIntroduction: Myasthenia gravis, an autoimmune disorder of neur A prospective open label multicentre study of 34 patients with refractory generalised myasthenia gravis treated with Zytux (a rituximab biosimilar) showed reduced disease activity and improved quality of life.13 Although these data are encouraging, the BeatMG (B Cell Targeted Treatment in Myasthenia Gravis) study, a phase 2 randomised ... Jun 13, 2013 · Background: A subset of myasthenia gravis (MG) patients is refractory to standard therapies. Identifying the characteristics of this population is essential as newer treatment strategies emerge that may be more effective in this group.Objective: The aim ... Apr 1, 2021 · Context and Policy Issues. Myasthenia gravis is a c View/Print PDF. Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder that causes skeletal muscle fatigable weakness and is the most common neuromuscular disorder. 1 Management of MG is based on clinical severity of symptoms, type of autoantibody involved, age, comorbidities, and the presence of thymoma. Myasthenia gravis (MG) is a relatively rare a...

Continue Reading